Clinical Trial Update: Brief Title: Study of Efficacy and Safety of Canakinumab as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) Completely Resected Non-small Cell Lung Cancer Acronym: CANOPY-A [Phase 3]

View source ↗

Summary

CANOPY-A is a Phase 3 trial evaluating canakinumab as adjuvant therapy for completely resected non-small cell lung cancer. The study was terminated and results …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• ILARIS (canakinumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Non-Small Cell Lung Cancer | Phase 3 | Status: TERMINATED | Results posted: 2024-01-30